

Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/T11F196E9798EN.html>

Date: March 2022

Pages: 233

Price: US\$ 2,000.00 (Single User License)

ID: T11F196E9798EN

Abstracts

Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 8, 9, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Thromboembolism - Overview
- Thromboembolism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Thromboembolism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Thromboembolism - Companies Involved in Therapeutics Development
- Acticor Biotech SAS
- Alexion Pharmaceuticals Inc
- Alfasigma SpA
- Anthos Therapeutics Inc
- Bayer AG
- Bio-Synectics Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- China Biologic Products Holdings Inc
- China Resources Emde Biological Pharmaceutical Co Ltd
- CSPC Pharmaceutical Group Ltd
- Espero BioPharma Inc
- EVAS Therapeutics LLC
- GC Pharma
- Indiana Lysis Technologies LLC
- Ionis Pharmaceuticals Inc
- IPCA Laboratories Ltd
- Jiangsu Hengrui Medicine Co Ltd
- KLUS Pharma Inc
- Kolmar Korea Co Ltd
- Laboratorios Farmaceuticos Rovi SA
- Ono Pharmaceutical Co Ltd

PharmaDiall
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tetherex Pharmaceuticals Corp
Tianjin Pharmaceuticals Group Co Ltd
Translational Sciences Inc
Verseon Corp
Thromboembolism - Drug Profiles
A-336 - Drug Profile
Product Description
Mechanism Of Action
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
antithrombin III (human) - Drug Profile
Product Description
Mechanism Of Action
apixaban - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-10 - Drug Profile
Product Description
Mechanism Of Action
betrixaban - Drug Profile
Product Description
Mechanism Of Action
History of Events
dabigatran etexilate mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
DD-217 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs for Pulmonary Embolism - Drug Profile

Product Description
Mechanism Of Action
enoxaparin sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
GC-2107 - Drug Profile
Product Description
Mechanism Of Action
History of Events
glenzocimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
HR-17020 - Drug Profile
Product Description
Mechanism Of Action
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
History of Events
KKM-183A - Drug Profile
Product Description
Mechanism Of Action
Lysimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
milvexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONO-7684 - Drug Profile
Product Description
Mechanism Of Action
History of Events
osocimab - Drug Profile
Product Description
Mechanism Of Action

History of Events

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism -
Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein for Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

reteplase - Drug Profile

Product Description

Mechanism Of Action

rivaroxaban - Drug Profile

Product Description

Mechanism Of Action

History of Events

rivaroxaban - Drug Profile

Product Description

Mechanism Of Action

SelK-2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SHR-2285 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Staphylokinase - Drug Profile

Product Description

Mechanism Of Action

History of Events

sulodexide - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYHA-136 - Drug Profile

Product Description

Mechanism Of Action

TAP-ANV - Drug Profile

Product Description

Mechanism Of Action

History of Events

tecarfarin sodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

TF-0023 - Drug Profile

Product Description

Mechanism Of Action

urokinase - Drug Profile

Product Description

Mechanism Of Action

History of Events

VE-2851 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YG-001 - Drug Profile

Product Description

Mechanism Of Action

Zifa-01 - Drug Profile

Product Description

Mechanism Of Action

Thromboembolism - Dormant Projects

Thromboembolism - Discontinued Products

Thromboembolism - Product Development Milestones

Featured News & Press Releases

Dec 20, 2021: FDA approves two new indications for XARELTO (rivaroxaban) to help prevent and treat blood clots in pediatric patients

Nov 16, 2021: Janssen-BMS' drug reduces venous thromboembolism risk in Phase II TKR trial

Nov 10, 2021: Hengrui Medicine's new anti-thrombotic drug, a new class 1 drug SHR2285 tablets phase II clinical trial approved

Jun 21, 2021: FDA approves first oral blood thinning medication for children

May 10, 2021: Bayer announces late-breaking presentations which include data from VOYAGER PAD (Xarelto)

Mar 11, 2021: Lee's Pharmaceutical: Voluntary announcement - Update on an investigational direct oral anticoagulant

Feb 01, 2021: Bayer receives approval in the UK for Xarelto (rivaroxaban) to treat

children with venous thromboembolism (VTE) and to Prevent VTE recurrence

Jan 22, 2021: Japan approves rivaroxaban (Xarelto) to treat children with venous thromboembolism and to prevent recurrence

Nov 16, 2020: Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age

Nov 13, 2020: Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children

Mar 29, 2020: Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery

Mar 29, 2020: Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery

Mar 20, 2020: Janssen Highlight presentation on XARELTO at American College of Cardiology Scientific Session

Feb 21, 2020: Secondary analysis confirms safety of blood thinning agent

Dec 07, 2019: Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Thromboembolism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Thromboembolism - Pipeline by Acticor Biotech SAS, 2022
Thromboembolism - Pipeline by Alexion Pharmaceuticals Inc, 2022
Thromboembolism - Pipeline by Alfasigma SpA, 2022
Thromboembolism - Pipeline by Anthos Therapeutics Inc, 2022
Thromboembolism - Pipeline by Bayer AG, 2022
Thromboembolism - Pipeline by Bio-Synectics Inc, 2022
Thromboembolism - Pipeline by Boehringer Ingelheim International GmbH, 2022
Thromboembolism - Pipeline by Bristol-Myers Squibb Co, 2022
Thromboembolism - Pipeline by China Biologic Products Holdings Inc, 2022
Thromboembolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2022
Thromboembolism - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Thromboembolism - Pipeline by Espero BioPharma Inc, 2022
Thromboembolism - Pipeline by EVAS Therapeutics LLC, 2022
Thromboembolism - Pipeline by GC Pharma, 2022
Thromboembolism - Pipeline by Indiana Lysis Technologies LLC, 2022
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, 2022
Thromboembolism - Pipeline by IPCA Laboratories Ltd, 2022
Thromboembolism - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Thromboembolism - Pipeline by KLUS Pharma Inc, 2022
Thromboembolism - Pipeline by Kolmar Korea Co Ltd, 2022
Thromboembolism - Pipeline by Laboratorios Farmaceuticos Rovi SA, 2022
Thromboembolism - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Thromboembolism - Pipeline by PharmaDiall, 2022

Thromboembolism - Pipeline by Supergene LLC, 2022
Thromboembolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
Thromboembolism - Pipeline by Techfields Pharma Co Ltd, 2022
Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, 2022
Thromboembolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2022
Thromboembolism - Pipeline by Translational Sciences Inc, 2022
Thromboembolism - Pipeline by Verseon Corp, 2022
Thromboembolism - Dormant Projects, 2022
Thromboembolism - Dormant Projects, 2022 (Contd..1)
Thromboembolism - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Thromboembolism, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/T11F196E9798EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T11F196E9798EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

